Gonadorelin Reconstitution Calculator

Gonadorelin is the synthetic, native-sequence form of gonadotropin-releasing hormone (GnRH), the hypothalamic peptide that drives pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release (mechanistic). Because the native sequence is rapidly degraded, it is always given by injection. A single dose produces a self-limited LH surge peaking 30–45 minutes after IV injection, and enough to trigger ovulation or testosterone secretion; pulsatile delivery mimics physiology well enough to restore spermatogenesis in gonadotropin-deficient men.

Human indications are narrow but established: the GnRH stimulation test remains the diagnostic gold standard for central precocious puberty [1,4], and pulsatile pump administration is standard clinical practice for hypogonadotropic hypogonadism (guideline). Veterinary formulations such as Factrel are labeled for estrus synchronization at 100–200 µg IM. Single-injection use outside diagnostic testing or fertility treatment has no clinical evidence base (practitioner consensus).

Depot agonists (triptorelin, leuprorelin, goserelin) are D-amino-acid-modified analogs that suppress testosterone to castrate levels (≤50 ng/dL) with sustained use. Gonadorelin is the native sequence, acts for minutes, and stimulates rather than suppresses the axis when pulsed [1,3]. It is also weaker per dose: in ewes, 50–100 µg gonadorelin produced lower peak LH than buserelin, lecirelin, or deslorelin (animal), and cattle ovulatory response is dose-dependent, 200 µg outperforms 100 µg IM.

Diagnostic stimulation test: 100 µg IV bolus with blood drawn at 0, 30, and 45 min; peak LH occurs by 30–60 min [8,2]. In girls, a peak LH ≥4.7 IU/L indicates central pubertal activation. Interpretation is weight-sensitive, obese girls with CPP have blunted peaks (median 6.2 vs 9.1 mIU/mL), and current guidelines favor basal ultrasensitive LH before reflexively ordering stimulation testing. Fertility therapy: 16 µg SC every 120 min via portable pump is a documented protocol (case report); 3 months of pulsatile GnRH induced monofollicular ovulation in all 41 women with functional hypothalamic amenorrhea, and azoospermic hypogonadotropic men achieved spermatogenesis earlier than with cyclical hCG/HMG (median 6 vs 14 months).

IV for diagnostic testing, SC for pump delivery, IM for triggering (100–200 µg in cattle ); there is no viable oral form (practitioner consensus). Gonadorelin degrades in aqueous solution with fully characterized kinetics (in-vitro); reconstituted vials are short-lived unless in an engineered formulation, a Zn2+-coordinated depot released gonadorelin continuously for 14 days in vitro. Refrigerate lyophilized material and use reconstituted product promptly (practitioner consensus).

Anaphylaxis after IV gonadorelin acetate has been reported in a child during stimulation testing, first doses warrant supervised administration (case report). Pump therapy commonly causes infusion-site erythema/scleroma but fewer androgenic complaints (acne, breast tenderness) than hCG/HMG cycles. Because pulsatile use stimulates the axis, bone mineral density and metabolic markers improved over 6 months in hypogonadotropic men. Gonadorelin is an ovulation-induction agent, not a pregnancy drug; discontinue once ovulation or pregnancy is confirmed (practitioner consensus).